Shares of G1 Therapeutics Inc. (NASDAQ:GTHX) rose 20% to $37.15 in after-hours trading after FDA approved Cosela trilaciclib to decrease bone marrow suppression caused by chemotherapy in adults being treated for extensive-stage small cell lung cancer. It’s the first therapy approved for the indication, according to FDA, and the first approval for G1. The company, which will launch Cosela next month, is co-marketing the therapy with Boehringer Ingelheim GmbH.
Seagen’s Tuksya gains EU approval
The European Commission approved Tuksya tucatinib from Seagen Inc. (NASDAQ:SGEN) plus trastuzumab and capecitabine to treat HER2-positive breast cancer in a third-line setting. The oral tyrosine kinase inhibitor that selectively targets HER2 received FDA approval in April 2020...